ISSN: 2165-7904

Journal of Obesity & Weight Loss Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Obes Weight Loss Ther 2022, Vol 12(8): 511

Omitted Liver Disease Screening in Acute Coronary Syndrome (ACS) Hides Prevalence of High Levels of Severe Liver Fibrosis

Saliu D1, Veys S1, Reynolds RC1, Mandour O Mandour1* and Oben JA1,2
1Guy's and St Thomas'NHS Foundation Trust London, Department of Gastroenterology and Hepatology, UK
2University College London, Institute for Institute for Liver and Digestive Health, United Kingdom
*Corresponding Author : Mandour O Mandour, Guy's and St Thomas' NHS Foundation Trust London, Department of Gastroenterology and Hepatology, UK, Email: omer.mandour@nhs.net

Received Date: Aug 03, 2022 / Published Date: Aug 30, 2022

Abstract

Background and Aims: Non-alcoholic fatty liver disease (NAFLD) has important associations with the metabolic syndrome and shares features with cardiovascular diseases, such as acute coronary syndrome (ACS). It is not standard of care to screen ACS patients for liver disease. We sought, to determine what proportion of patients presenting with ACS had full liver functions tests (LFTs) performed, and using available LFTs assessed for liver fibrosis.

Methods: Retrospective study of patients admitted with ACS to St Thomas’ teaching hospital between 01/09/17 and 31/08/18. We determined if full LFTs had been measured to allow calculation of a fibrosis score. As a secondary outcome we audited metabolic parameters for each patient. This study was exempt from IRB review.

Results: 360/521 patients (69%) met inclusion criteria of having an acute admission due to ACS: 272 males and 88 females, aged 34-91. 181(50%) had an ST elevation Myocardial infarction (STEMI), 176(49%) had a Non-ST elevation Myocardial Infarction (NSTEMI), and 3 had an unspecified ACS. 30 (8.3%) had sufficient tests performed to calculate FIB-4; 263(72%) had basic LFTs performed, and 67(19%) had no LFTs measured. Of the 30 with sufficient tests, 47% had a FIB-4 score >3.25, indicating advanced liver fibrosis (bridging fibrosis or cirrhosis). Only 2 had pre-existing known liver disease including NAFLD.

Conclusion: Few patients presenting with ACS are assessed for liver fibrosis. A change in standard of care to performing a full liver screen on patients admitted with ACS would allow for the increased diagnosis of liver fibrosis.

Citation: Saliu D, Veys S, Reynolds RC, Mandour MO, Oben JA (2022) OmittedLiver Disease Screening in Acute Coronary Syndrome (ACS) Hides Prevalence ofHigh Levels of Severe Liver Fibrosis. J Obes Weight Loss Ther 12: 511.

Copyright: © 2022 Saliu D. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

Top